Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of cheaper, safer pharmaceuticals as well as alleviating animal suffering. But according to a new paper co-written by a University of Illinois Urbana-Champaign expert in legal issues surrounding cutting-edge medical developments, such a novel approach to drug trials needs to be implemented judiciously and with caution.
This article was originally published on MedicalXpress.com

